title: Increased Expression of Phosphorylated Polo-Like Kinase 1 and Histone in Bypass Vein Graft and Coronary Arteries following Angioplasty.
abstract: Interventional procedures, including percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass surgery (CABG) to re-vascularize occluded coronary arteries, injure the vascular wall and cause endothelial denudation and medial vascular smooth muscle cell (VSMCs) metaplasia. Proliferation of the phenotypically altered SMCs is the key event in the pathogenesis of intimal hyperplasia (IH). Several kinases and phosphatases regulate cell cycle in SMC proliferation. It is our hypothesis that increased expression and activity of polo-like kinase-1 (PLK1) in SMCs, following PTCA and CABG, contributes to greater SMC proliferation in the injured than uninjured blood vessels. Using immunofluorescence (IF), we assessed the expression of PLK1 and phosphorylated-PLK1 (pPLK1) in post-PTCA coronary arteries, and superficial epigastric vein grafts (SEV) and compared it with those in the corresponding uninjured vessels. We also compared the expressions of mitotic marker phospho-histone, synthetic-SMC marker, contractile SMC marker, IFN-γ and phosphorylated STAT-3 in the post-PTCA arteries, SEV-grafts, and the uninjured vessels. Immunostaining demonstrated an increase in the number of cells expressing PLK1 and pPLK1 in the neointima of post PTCA-coronary arteries and SEV-grafts compared to their uninjured counterparts. VSMCs in the neointima showed an increased expression of phospho-histone, synthetic and contractile SMC markers, IFN-γ and phosphorylated STAT-3. However, VSMCs of uninjured coronaries and SEV had no significant expression of the aforementioned proteins. These data suggest that PLK1 might play a critical role in VSMC mitosis in hyperplastic intima of the injured vessels. Thus, novel therapies to inhibit PLK1 could be developed to inhibit the mitogenesis of VSMCs and control neointimal hyperplasia.
authors.affiliation: Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE, United States of America.
authors.forename: Swastika
authors.initials: S
authors.lastname: Sur
authors.affiliation: Department of Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE, United States of America.
authors.forename: Vicki J
authors.initials: VJ
authors.lastname: Swier
authors.affiliation: Department of Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE, United States of America.
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Radwan
authors.affiliation: Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE, United States of America.|Department of Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE, United States of America.
authors.forename: Devendra K
authors.initials: DK
authors.lastname: Agrawal
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D018797:Cell Cycle Proteins / Q000378:metabolism*; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000378:metabolism / Q000628:therapy*; D003331:Coronary Vessels / Q000378:metabolism* / Q000601:surgery; D006657:Histones / Q000378:metabolism*; D007371:Interferon-gamma / Q000378:metabolism; D018995:Myosin Heavy Chains / Q000378:metabolism; D024501:Nonmuscle Myosin Type IIB / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D034421:Sus scrofa; D000097869:Polo-Like Kinase 1
chemical_list: D018797:Cell Cycle Proteins; D006657:Histones; D007371:Interferon-gamma; D018995:Myosin Heavy Chains; D024501:Nonmuscle Myosin Type IIB; D010750:Phosphoproteins; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1; C103815:nonmuscle myosin type IIB heavy chain
references.citation: Nat Rev Mol Cell Biol. 2009 Apr;10(4):265-75
references.pmid: 19305416
references.citation: J Cell Sci. 2003 Sep 15;116(Pt 18):3677-85
references.pmid: 12917355
references.citation: J Cutan Pathol. 2002 Jul;29(6):354-8
references.pmid: 12135466
references.citation: Can J Physiol Pharmacol. 2014 Jul;92(7):531-45
references.pmid: 24933515
references.citation: Tissue Eng Part B Rev. 2010 Oct;16(5):467-91
references.pmid: 20334504
references.citation: Mol Cell Biol. 2002 Feb;22(3):874-85
references.pmid: 11784863
references.citation: PLoS One. 2012;7(8):e42789
references.pmid: 22880111
references.citation: J Biol Chem. 2004 Oct 1;279(40):41679-85
references.pmid: 15284232
references.citation: Cell. 2007 Nov 30;131(5):847-60
references.pmid: 18045532
references.citation: Oncogene. 2002 May 9;21(20):3162-71
references.pmid: 12082631
references.citation: J Cell Mol Med. 2009 Mar;13(3):547-54
references.pmid: 18544045
references.citation: Cancer Lett. 2001 Mar 10;164(1):41-9
references.pmid: 11166914
references.citation: Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1736-40
references.pmid: 8127874
references.citation: J Cell Biol. 1996 Dec;135(6 Pt 2):1701-13
references.pmid: 8991084
references.citation: Am Heart J. 1999 Nov;138(5 Pt 2):S419-20
references.pmid: 10539839
references.citation: Curr Biol. 2007 Feb 20;17(4):316-22
references.pmid: 17291758
references.citation: J Am Coll Cardiol. 1996 Sep;28(3):616-26
references.pmid: 8772748
references.citation: Nature. 2000 Sep 14;407(6801):233-41
references.pmid: 11001066
references.citation: Histol Histopathol. 2016 Feb;31(2):167-76
references.pmid: 26260796
references.citation: Circ Res. 2007 Sep 14;101(6):542-4
references.pmid: 17872472
references.citation: Protein Cell. 2012 Mar;3(3):182-97
references.pmid: 22447658
references.citation: Prostate. 2004 Aug 1;60(3):240-5
references.pmid: 15176053
references.citation: Keio J Med. 2001 Sep;50(3):152-60
references.pmid: 11594037
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3352-65
references.pmid: 22535157
references.citation: Clin Cancer Res. 2009 May 1;15(9):3094-102
references.pmid: 19383823
references.citation: Ann Surg Oncol. 2001 Oct;8(9):729-40
references.pmid: 11597015
references.citation: Nature. 2001 Mar 8;410(6825):215-20
references.pmid: 11242082
references.citation: Nat Rev Drug Discov. 2010 Aug;9(8):643-60
references.pmid: 20671765
references.citation: Chromosoma. 2012 Dec;121(6):565-72
references.pmid: 22566210
references.citation: Cell Div. 2006 May 18;1:8
references.pmid: 16759363
references.citation: Pathol Res Pract. 2000;196(11):753-9
references.pmid: 11186170
references.citation: Cell Cycle. 2006 Apr;5(8):853-64
references.pmid: 16627997
references.citation: Cancer Lett. 2001 Aug 10;169(1):41-9
references.pmid: 11410324
references.citation: Curr Opin Cell Biol. 2008 Dec;20(6):650-60
references.pmid: 19000759
references.citation: Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52
references.pmid: 24954208
references.citation: J Cell Sci. 2001 Jul;114(Pt 13):2357-8
references.pmid: 11559744
references.citation: J Vasc Surg. 1986 Jan;3(1):104-14
references.pmid: 3510323
references.citation: Am J Pathol. 1997 Apr;150(4):1165-72
references.pmid: 9094972
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8672-6
references.pmid: 12077309
references.citation: Dev Cell. 2008 May;14(5):646-59
references.pmid: 18477449
references.citation: Genes Dev. 1998 Dec 15;12(24):3777-87
references.pmid: 9869630
references.citation: Exp Cell Res. 2013 Dec 10;319(20):3104-15
references.pmid: 24076372
references.citation: Circ Res. 2007 Sep 14;101(6):560-9
references.pmid: 17656678
references.citation: Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40
references.pmid: 15173822
references.citation: Clin Cancer Res. 2011 Jul 1;17(13):4285-95
references.pmid: 21610149